Junior Research Group RNA Biology of Fungal Infections, Leibniz Institute for Natural Product Research and Infection Biology - Hans Knöll Institute (Leibniz-HKI), Jena, Germany.
Junior Research Group RNA Biology of Fungal Infections, Leibniz Institute for Natural Product Research and Infection Biology - Hans Knöll Institute (Leibniz-HKI), Jena, Germany.
Trends Microbiol. 2022 May;30(5):411-420. doi: 10.1016/j.tim.2021.09.007. Epub 2021 Oct 8.
In recent decades, RNA-based therapeutics have transitioned from a near impossibility to a compelling treatment alternative for genetic disorders and infectious diseases. The mRNA vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are truly groundbreaking, and new adaptations are already being proposed to fight other microbes. Unfortunately, the potential of RNA-based therapeutics to treat human fungal infections has remained mostly absent from the conversation, despite the fact that invasive fungal infections kill as many per year as tuberculosis and even more than malaria. Here, we argue that RNA-based therapeutics should be investigated for the treatment of human fungal infections and discuss several major roadblocks and potential circumventions that may allow for the realization of RNA-based therapies against human fungal pathogens.
近几十年来，基于 RNA 的疗法已经从几乎不可能的事情转变为治疗遗传疾病和传染病的一种有吸引力的治疗选择。针对严重急性呼吸综合征冠状病毒 2 (SARS-CoV-2) 的 mRNA 疫苗是真正具有开创性的，已经提出了新的适应方法来对抗其他微生物。不幸的是，尽管侵袭性真菌感染每年导致的死亡人数与结核病相当，甚至超过疟疾，但基于 RNA 的疗法治疗人类真菌感染的潜力在很大程度上仍未被提及。在这里，我们认为应该研究基于 RNA 的疗法来治疗人类真菌感染，并讨论可能允许实现针对人类真菌病原体的基于 RNA 的治疗的几个主要障碍和潜在规避方法。
